| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/10/2004 | WO2004006856A3 Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression |
| 06/10/2004 | WO2004006801A3 Treatment for dry eye syndrome |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2004002447A3 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton |
| 06/10/2004 | WO2004000225A3 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| 06/10/2004 | WO2003102140A3 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis |
| 06/10/2004 | WO2003101950A3 Methods for enhancing motor performance and/or endurance |
| 06/10/2004 | WO2003097656A3 Novel substituted sulfamate anticonvulsant derivatives |
| 06/10/2004 | WO2003090754A9 Use of dhea for treatment of female hypopituitarism |
| 06/10/2004 | WO2003087323A3 Biologic modulations with nanoparticles |
| 06/10/2004 | WO2003087307A3 Use of interleukin-19 to treat cervical cancer |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003080037A3 Use of ltb4 antagonists in veterinary medicine |
| 06/10/2004 | WO2003074060A8 Dna demethylase antisense and chemotherapy combination |
| 06/10/2004 | WO2003072027A3 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003070191A8 Tamper-resistant transdermal opioid delivery devices |
| 06/10/2004 | WO2003066842A3 Method for producing recombinant proteins in micro-organisms |
| 06/10/2004 | WO2003066005A3 Ansamycins having improved pharmacological and biological properties |
| 06/10/2004 | WO2003064626A3 Double-stranded oligonucleotides |
| 06/10/2004 | WO2003059265A3 Compositions and methods for treating heart failure |
| 06/10/2004 | WO2003048116A3 Esters and amides as ppar-alpha agonists ____________ |
| 06/10/2004 | WO2003043972A3 Functional acylglycerides |
| 06/10/2004 | WO2003040170A9 Antibodies to cd40 |
| 06/10/2004 | WO2003037258A3 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 06/10/2004 | WO2003035080A3 A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 06/10/2004 | WO2003035049A3 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 06/10/2004 | WO2003024433A3 Compositions for treatment of common cold, comprising ipratropium and xylometazoline |
| 06/10/2004 | WO2003024298A9 Interspinous process implant sizer and distractor with a split head and size indicator and method |
| 06/10/2004 | WO2003015711A3 Combination motif immune stimulatory oligonucleotides with improved activity |
| 06/10/2004 | WO2003007800A9 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 06/10/2004 | WO2002053091A3 Medicinal combination of a biguanine (metformin) and arginine |
| 06/10/2004 | WO2002040629A3 Promoters exhibiting endothelial cell specificity and methods of using same |
| 06/10/2004 | US20040111763 for introducing DNA into organisms which produce large amounts of oils; genetic engineering; for animal feed, foods, cosmetics and pharmaceuticals; kits |
| 06/10/2004 | US20040111760 Production of stilbenes in transgenic plants and the method of producing thereof |
| 06/10/2004 | US20040110966 2-methylenetetrahydro-2(5H)-furanone derivatives, their preparation from 4-oxovaleric acids, and homo-and copolymers of the furanones |
| 06/10/2004 | US20040110963 Novel hydrazones |
| 06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
| 06/10/2004 | US20040110947 such as methyl-3-[([2-[(3-chloro-2,2-dimethylpropanoyl)amino]phenyl]thio)methyl]benzoate; lipid/lipoprotein metabolism |
| 06/10/2004 | US20040110946 such as ethyl-2-[6-amino-4-(1,3-benzodioxol-5-yl)-3,5-dicyano-2-pyridinyl]propionate; drug screening; for treatment of cardiovascular disorders/diabetes |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110849 for inhibiting the progression of atherosclerosis, comprising the administration of an effective anti-LDL (low density lipoproteins)-oxidation amount of phytoene, phytofluene or mixtures thereof |
| 06/10/2004 | US20040110848 by inhibiting overproduction of HMG-CoA mRNA, the enhanced translation of HMG-CoA reductase from mRNA, the elevated 4E-BP1 phosphorylation, the overexpression of eIF4E, increased levels/activity of matrix metalloproteinases (MMPs) |
| 06/10/2004 | US20040110846 Perylenequinones for use with immunotherapy agents |
| 06/10/2004 | US20040110845 aqueous inhalation compositions containing albuterol; a buffer, such as citric acid; and a metal chelator, such as EDTA; for treating, preventing, or ameliorating symptoms of bronchoconstrictive disorders such as asthma |
| 06/10/2004 | US20040110844 has a low side-effect and a high anti-tumor effect, in particular an anti-melanoma effect and an anti-leukemia cell effect; and is very low pungent, stimulatory and preinflammatory effect |
| 06/10/2004 | US20040110843 in a patient suffering from a co-morbid condition comprising placing in the fossa navicularis a semi-solid composition comprising a vasoactive prostaglandin and a penetration enhancer; co-morbid condition is diabetes mellitus, hypertension, etc |
| 06/10/2004 | US20040110842 Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect |
| 06/10/2004 | US20040110841 Antiseptic compositions, methods and systems |
| 06/10/2004 | US20040110840 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/10/2004 | US20040110839 Compounds and compositions for delivering active agents |
| 06/10/2004 | US20040110838 side effect reduction of anticarcinogenic agents, by administering irinotecan and/or taxol, with group VI compounds such as seleno-L-methionine |
| 06/10/2004 | US20040110837 use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3) to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (A beta ) peptides which are believed to be the cause of Alzheimer's |
| 06/10/2004 | US20040110836 Treating chronic uremic patients undergoing periodical dialysis |
| 06/10/2004 | US20040110835 used as a pharmaceutical, foodstuff, dietary supplement, or cosmetic; Inflammation related diseases that may be treated include to rheumatoid arthritis, osteoarthritis, psoriasis, monoarthritis, gout, collagen vascular disease |
| 06/10/2004 | US20040110834 can be used as a medicament, food for special healty uses and a health food that are effective for protection against infection of microorganisms such as pathogenic Escherichia coli such as E. coli or Helicobacter pylori. |
| 06/10/2004 | US20040110833 administering a patient an ester of an alpha-ketoalkanoic acid selected from alpha-ketopropionic acid (pyruvate), alpha-keto-butyrate, alpha-ketopentanoate, alpha-keto-3-methyl-pentanoate etc. to treat cytokine mediated inflammatory conditions |
| 06/10/2004 | US20040110832 management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc |
| 06/10/2004 | US20040110831 Urokinase inhibitors |
| 06/10/2004 | US20040110830 20-hydroxyeicosatetraenoic acid (HETE); useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases |
| 06/10/2004 | US20040110829 treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with/without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa |
| 06/10/2004 | US20040110828 for treating, lessening, or ameliorating emesis, anorexia, or chronic or AIDS-related wasting syndrome |
| 06/10/2004 | US20040110827 Has the 3S,4S configuration and is >99.90% over the 3R,4R enantiomer; nervous system disorders; chronic neurodegenerative diseases, CNS poisoning, cognition activators; antiinflammatory agents; autoimmune diseases; side effect reduction |
| 06/10/2004 | US20040110826 Alpha 2c-adrenoceptor antagonists comprising 1- (benzylamino)-1,2,4]triazolo[1,5-c]pyrimidine derivatives; Parkinson's disease, dyskinesias, antidepressants; hypotensive, antidiabetic agents; eating,sexual disorders |
| 06/10/2004 | US20040110825 Method for treating sepsis |
| 06/10/2004 | US20040110824 2-Phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 06/10/2004 | US20040110823 Bone disorders; cardiovascualr disorders; hormone replacement therapy |
| 06/10/2004 | US20040110821 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative |
| 06/10/2004 | US20040110819 Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| 06/10/2004 | US20040110818 Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| 06/10/2004 | US20040110813 using less complicated and expensive long-lasting stability of the formulation under different climatic conditions and sufficient solubility of the active substance for sufficient gastrointestinal absorption in the slightly acidic and neutral pH |
| 06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
| 06/10/2004 | US20040110809 di- and tricycle-substituted imidazolidine-, oxazolidine- and thiazolidine diones and thiones, e.g., 5-[p-(quinolin-3-yl)-alpha-hydroxybenzyl]-5-methylimidazolidinedione |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110803 especially salts, prodrugs or active derivatives thereof; optionally coadministering a compound that interferes with fatty acid synthesis. |
| 06/10/2004 | US20040110801 Prevention of degenerative joint diseases, rheumatoid arthritis, osteoarthritis, ulcerative colitis, irritable colon and Crohn's diseas, antitumor agents; drug mixture for transdermal drug delivery, sustained release; chemical synthesis |
| 06/10/2004 | US20040110800 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 06/10/2004 | US20040110799 Use of a PPAR-alpha agonist to treat patients suffering from weight gain associated with a PPAR-gamma agonist treatment |
| 06/10/2004 | US20040110798 A pyridyl-2yl-4-[1,2,3-triazole] derivatives therapeutic agent for treating cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, hyperplasia, restenosis, skin disorders |
| 06/10/2004 | US20040110795 Use of iminosugar derivatives to inhibit ion channel activity |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110793 Heterocyclo inhibitors of potassium channel function |
| 06/10/2004 | US20040110792 Methods for assessing and treating leukemia |
| 06/10/2004 | US20040110791 A 2-(naphthalene, quinoline, or benzothiophene-2-yl)-ethylamine derivatives, controlling of intraocular pressure, treating vision defects |
| 06/10/2004 | US20040110788 A 2-azabicyclo-[2.2.1]hept-7yl derivatives, treating schizophrenia, depression, anxiety, dementia, Alzheimer's disease, neurodegenerative disorders, Parkinson's disease, Huntington's disease, Tourette's syndrome; chemical intermediates |
| 06/10/2004 | US20040110784 Remedies for vesical stimulation association with prostatauxe |
| 06/10/2004 | US20040110781 Pharmaceutical compositions containing indistinguishable drug components |
| 06/10/2004 | US20040110779 Hydantoin derivsatives with affinity for somatostatin receptors |
| 06/10/2004 | US20040110778 A 3,10-diaza-benzo[e]azulene, 3,8,10-triaza-benzo[e]azulene, or 1,3a,6-triaza-as-indacene derivatives, used to treat anxiety, depression, a sleep disorder, or Alzheimer's dementia. |
| 06/10/2004 | US20040110776 Associated with glaucoma or ocular hypertension; propentofylline was unexpectedly discovered to stimulate the expression of metalloproteinase-3 (MMP-3; stromelysin) in cultured human trabecular meshwork cells |
| 06/10/2004 | US20040110775 Cyclin dependent kinase inhibiting purine derivatives |
| 06/10/2004 | US20040110774 HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID); antagonists are antibodies |
| 06/10/2004 | US20040110772 Inhibitors of nucleoside phosphorylases and nucleosidases |
| 06/10/2004 | US20040110769 Antitumor agents for cancer treatment; 5-(3-chlorophenyl)-alpha-(4-chlorophenyl)-alpha-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine with tamoxifen for example |
| 06/10/2004 | US20040110768 (S)-3-(1H-indol-3-yl)-N-(1-methoxymethyl-cyclohexylmethyl)-2-methyl-2-[4-(4-nitro-phenyl)-oxazol-2-ylamino]-propionamide for example; cancer, psychological disorders, sexual disorders, eating disorders, inflammatory bowel disease, sleep disorders |
| 06/10/2004 | US20040110766 Benzimidazoles that are useful in treating sexual dysfunction |
| 06/10/2004 | US20040110764 Inhibit oncogene Ras; treating neurofibromin benign proliferative disorder; cancer (combination therapy); blindness, hepatitis infection, restenosis, polycystic kidney disease; imidazo[2,1-b]thiazole derivatives for example |